09.04.19
Altasciences has appointed Dr. Lynne LeSauteur, PhD, to its bioanalytical management team, responsible for the Bioanalytical Services department in the U.S. and the Ligand Binding team in Canada.
Most recently, Dr. LeSauteur was director of Downstream Processing and Analytics as well as Program Leader Biologics and Biomanufacturing for the Human Health Therapeutics Research Center at the National Research Council of Canada (NRC), where she led numerous teams and initiatives to discover, manufacture, and characterize novel biologics for unmet needs, in collaboration with biopharmaceutical companies. Prior to the NRC, Lynne worked at Charles River Laboratories where she established the Immunology Department, and led the scientific and strategic growth of that group from one to over 80 employees, effectively delivering expertise to sponsors in progressing numerous biologics through the drug development value chain.
“We are extremely pleased to welcome Lynne to the team at Altasciences. The breadth of her experience in both preclinical and clinical drug development, including her in-depth knowledge of immunotoxicology, immunogenicity, immunoassays, molecular biology, and biomarkers, will continue to enhance scientific guidance to our growing base of small- to mid-size clients,” said Marie-Hélène Raigneau, Executive Vice President, Research Services, at Altasciences.
Most recently, Dr. LeSauteur was director of Downstream Processing and Analytics as well as Program Leader Biologics and Biomanufacturing for the Human Health Therapeutics Research Center at the National Research Council of Canada (NRC), where she led numerous teams and initiatives to discover, manufacture, and characterize novel biologics for unmet needs, in collaboration with biopharmaceutical companies. Prior to the NRC, Lynne worked at Charles River Laboratories where she established the Immunology Department, and led the scientific and strategic growth of that group from one to over 80 employees, effectively delivering expertise to sponsors in progressing numerous biologics through the drug development value chain.
“We are extremely pleased to welcome Lynne to the team at Altasciences. The breadth of her experience in both preclinical and clinical drug development, including her in-depth knowledge of immunotoxicology, immunogenicity, immunoassays, molecular biology, and biomarkers, will continue to enhance scientific guidance to our growing base of small- to mid-size clients,” said Marie-Hélène Raigneau, Executive Vice President, Research Services, at Altasciences.